CA-ESRI
10.3.2022 14:02:10 CET | Business Wire | Press release
Governments and businesses across the world are pledging to adopt more sustainable and equitable practices. Many are also working to limit activities that contribute to climate change. To support these efforts, Esri , the global leader in location intelligence, in partnership with Impact Observatory and Microsoft, is releasing a globally consistent 2017–2021 global land-use and land-cover map of the world based on the most up-to-date 10-meter Sentinel-2 satellite data. In addition to the new 2021 data, 10-meter land-use and land-cover data for 2017, 2018, 2019, and 2020 is included, illustrating five years of change across the planet.
This digital rendering of earth's surfaces offers detailed information and insights about how land is being used. The map is available online to more than 10 million users of geographic information system (GIS) software through Esri's ArcGIS Living Atlas of the World , the foremost collection of geographic information and services, including maps and apps.
"Accurate, timely, and accessible maps are critical for understanding the rapidly changing world, especially as the effects of climate change accelerate globally," said Jack Dangermond, Esri founder and president. "Planners worldwide can use this map to better understand complex challenges and take a geographic approach to decisions about food security, sustainable land use, surface water, and resource management."
Esri released a 2020 global land-cover map last year as well as a high-resolution 2050 global land-cover map , showing how earth's land surfaces might look 30 years from now. With the planned annual releases, users will have the option to make year-to-year comparisons for detecting change in vegetation and crops, forest extents, bare surfaces, and urban areas.
These maps also provide insights about locations with distinctive land use/land cover, as well as human activity affecting them. National government resource agencies use land-use/land-cover data as a basis for understanding trends in natural capital, which helps define land-planning priorities and determine budget allocations.
Esri's map layers were developed with imagery from the European Space Agency (ESA) Sentinel-2 satellite, with machine learning workflows by Esri Silver partner Impact Observatory and incredible compute resources from longtime partner Microsoft. The Sentinel-2 satellite carries a range of technologies including radar and multispectral imaging instruments for land, ocean, and atmospheres, enabling it to monitor vegetation, soil and water cover, inland waterways, and coastal areas.
"World leaders need to set and achieve ambitious targets for sustainable development and environmental restoration," said Steve Brumby, Impact Observatory cofounder and CEO. "Impact Observatory [and] our partners Esri and Microsoft are once again first to deliver an annual set of global maps at unprecedented scale and speed. These maps of changing land use and land cover provide leaders in governments, industry, and finance with a new AI [artificial intelligence]-powered capability for timely, actionable geospatial insights on demand."
Esri and Microsoft have released this 10-meter-resolution time-series map under a Creative Commons license to encourage broad adoption and ensure equitable access for planners working to create a more sustainable planet. Users can manipulate the map layers and other data layers with GIS software to create more dynamic visualizations.
In addition to being freely available in ArcGIS Online as a map service, these resources are also available for download and viewing. To explore the new 2021 global land-use/land-cover map, visit livingatlas.arcgis.com/landcover .
About Impact Observatory
Impact Observatory develops AI-powered, on-demand, geospatial data that maps changing land use and land cover at unprecedented scale and speed. Impact Observatory provides world leaders in governments, industry, and finance with timely, actionable, data-driven insights for sustainability and environmental risk analysis. Impact Observatory is a U.S. technology company based in Washington, D.C.
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom